REGENXBIO Inc. (NASDAQ: RGNX) today announced financial results for the quarter ended September 30, 2018 and recent operational highlights ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Management Comments

Regenxbio (RGNX) Misses Q3 EPS by 12c, Revenues MissNovember 7, 2018 5:08 PM REGENXBIO Reports Third Quarter 2018 Financial and Operating Results and Announces Initiation of Phase I/II Clinical Trial for RGX-121 for the Treatment of MPS IINovember 7, 2018 4:05 PM Regenxbio (RGNX), Abeona (ABEO) Announce Worldwide Exclusive Licenses for Treatment of Four Rare Lysosomal Storage Disorders Using NAV AAV9 VectorNovember 5, 2018 7:16 AM